Sumitomo Pharma resolved at the Board of Directors meeting on April 8, 2026 to conduct a public offering of 51,304,400 new shares and a third-party allotment of 7,695,600 shares, planning to allocate the approximately JPY 116.49 billion raised to research and development and strengthening the financial base.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4506-20260408-01.pdf","jir_short_summary":"Sumitomo Pharma resolved at the Board of Directors meeting on April 8, 2026 to conduct a public offering of 51,304,400 new shares and a third-party allotment of 7,695,600 shares, planning to allocate the approximately JPY 116.49 billion raised to research and development and strengthening the financial base.","jir_summary":"### Overview of Capital Policy\nSumitomo Pharma Co., Ltd. resolved at the Board of Directors meeting on April 8, 2026, to issue 51,304,400 new shares through a public offering and 7,695,600 shares through a third-party allotment, along with a share offering. Simultaneous domestic and overseas offerings are planned, with the issue price to be determined between April 20 and 23, 2026. As a result, the total number of outstanding shares is expected to reach up to 456,900,154 shares.\n\n### Use of Funds Raised and Future Outlook\nThe estimated maximum funds of approximately JPY 116.49 billion will be allocated to clinical development funding in the oncology field (approximately JPY 30 billion), research and development funding for neurodegenerative diseases and infectious diseases (approximately JPY 10 billion), reinforcement of regenerative and cell therapy businesses (approximately JPY 10 billion), strengthening production and quality systems as well as IT system investments (approximately JPY 10 billion), and repayment of interest-bearing debt. These measures aim to strengthen the revenue and financial base and enhance corporate value over the medium to long term. Although the voting rights ratio of Sumitomo Chemical will decline, the status as a consolidated subsidiary will be maintained.","jir_financial_highlights":"Total Number of Outstanding Shares (Pre-Public Offering): 397,900,154 shares (Unknown)\nNumber of Shares Increased by Public Offering: 51,304,400 shares (Approx. 12.9% Dilution (vs. Pre-Public Offering))\nNumber of Shares Increased by Third-Party Allotment: 7,695,600 shares (Unknown)\nEstimated Maximum Amount of Funds Raised: 116,490,277,000 yen (Unknown)","jir_category":"","jir_hashtags":"#SumitomoPharma, #CapitalPolicy, #NewShareIssuance, #JapaneseStocks","jir_key_figures":"Number of Shares from Public Offering: 51,304,400 shares\nNumber of Shares from Third-Party Allotment: 7,695,600 shares\nEstimated Maximum Funds Raised: 116,490,277,000 yen","jir_meta_title":"Sumitomo Pharma Resolves to Raise Approximately JPY 116.4 Billion Through New Share Issuance to Strengthen Oncology and Other R&D","jir_meta_description":"Sumitomo Pharma Co., Ltd. resolved on April 8, 2026, to issue new shares and conduct a share offering, allocating approximately JPY 116.4 billion in funds to clinical development in oncology, strengthening regenerative medicine business, and reinforcing its financial base.","jir_og_title":"Sumitomo Pharma Resolves to Raise Approximately JPY 116.4 Billion Through New Share Issuance","jir_og_description":"Sumitomo Pharma will raise approximately JPY 116.4 billion through new share issuance and share offering, aiming to strengthen research and development and its financial base.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-39521","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n